AffaMed, headquartered in Shanghai with operating subsidiaries across North America and Greater China, is a global near-commercial stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in neurological and ophthalmic disorders for patients in Greater China and around the world. Since its inception in 2019, AffaMed has assembled world-class capabilities in clinical development, regulatory affairs, business development, and most recently commercialization, under the leadership of its CEO, Dr. Dayao Zhao, a seasoned industry veteran who has previously served as Head of China R&D for Pfizer; as Head of China R&D at Janssen; and as Genzyme's head of APAC R&D. The Company operates as a global platform with a focused and risk-balanced portfolio positioned to deliver return through both near-term commercial opportunities addressing major unmet need in China, combined with global value potential from first / best-in-class clinical stage innovation. The AffaMed investment proposition is centered around the following key value drivers: To date, AffaMed has raised US$250 million capital in first two rounds, including its US$170 million Series B round led by Lake Bleu Capital, with additional participation by Partners Investment, Superstring Capital, Orion Science Capital, and Fountainhead Partners, and with continuing support of its founding investor CBC Group.